|
?:abstract
|
-
The Covid-19 epidemic has placed considerable strain on healthcare systems in all countries The impacts are multiple for patients treated for cancer The objective of this manuscript is to summarize the epidemiological data available on patients with lung cancer developing a Covid infection, in particular the risk factors for aggravation and mortality, to describe the different strategies to improve the management of these patients and to summarize the existing recommendations in this area The largest cohort on this subject, Teravolt, which included 1012 patients, found a hospitalization rate of 72 %, an aggravation rate of 56 % and a mortality of 32 % In multivariate analysis, age >=65 years (OR 1 53 CI 1 11-2 1), active smoking (OR 2 CI 1 3-3), metastatic status (OR 1 9 CI 1, 3-2 7), an ECOG PS >=2 (OR 3 7 CI 2 7-5), taking corticosteroids before COVID infection (OR 1 8 CI 1 2-2 7), are associated with a higher risk of mortality but not treatments with chemotherapy or targeted therapies Interestingly, treatment with immunotherapy appears to decrease the risk of mortality (OR 0 6 CI 0 97)Several screening strategies for asymptomatic forms have been reported in the literature and seem useful for diagnosing asymptomatic forms in patients undergoing systemic treatment or radiotherapy Finally, national and international recommendations converge on many points, in particular for the need to protect patients and their families from Covid by assessing the benefit / risk of treatment on a case-by-case basis © 2020 SPLF Published by Elsevier Masson SAS All rights reserved
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}